The Latest Breaking News from Amgen

Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

Amgen handily beat earnings forecasts Tuesday, but Amgen stock tumbled after the company scrapped an experimental prostate cancer treatment.

The Dow Jones Industrial Average dropped 125 points Tuesday after key housing data. Tesla stock continued to slide after Monday's dive.

Amgen (AMGN) is scheduled to report its third-quarter earnings soon, with Wall Street analysts expecting year-over-year improvements in revenue. However, its earnings are expected to miss the consensus estimate. Moreover, the company completed the acquisition of Horizon Therapeutics earlier this month. Considering these factors, is the stock a buy or…

Microsoft, one of just two Magnificent Seven stocks to move higher last week, leads this watchlist of five Dow Jones stocks. near buy points.

350 people will be laid off, many of them at Horizon’s U.S. base in Deerfield.

Wall Street is never lacking in strategy or trading ideas. In investing, if you can combine two or more strategies that align around a particular investing idea, you can enhance your likelihood of success. This idea combines our POWR Ratings with a strategy that is currently making the rounds on…

Dow Jones rose after the Fed meeting minutes for September were released and the House planned to vote on a new speaker. Meta broke out.

Amgen stock snagged an upgrade Wednesday and surged to a 10-month high as one analyst examined the biotech behemoth's post-Horizon future.

Bristol Myers Squibb offered to buy Mirati Therapeutics for up to $5.8 billion, but MRTX stock tumbled on the lowball price.